Objective. We have tried to determine what baseline variables are responsible for remission induction at 6 months in rheumatoid arthritis (RA) patients treated with etanercept of Japanese population in unselected patients. Methods. One hundred forty-one patients with RA, etanercept being administrated, were registered. Thirty-four patients were started as etanercept monotherapy, 60 patients as cotherapy with methotrexate (MTX) (MTX cotherapy) and 47 patients as cotherapy with other non-MTX nonbiologic disease modifying antirheumatic drugs (DMARDs) (non-MTX cotherapy), respectively. None of the patients were treated with both MTX and non-MTX nonbiologic DMARDs at entry. The outcome was set as the achievement of Disease Activity Score (DAS) 28-ESR remission at 6 months. We have examined the association of gender, DAS at baseline, MTX cotherapy at baseline, non-MTX cotherapy at baseline and prednisolone use at baseline with the achievement of remission at 6 months by logistic regression analysis. Results. All of the subjects were classified as high disease activity (N=109) or moderate disease activity (N=32) at entry. One hundred twenty out of 141 patients (85.1%) continued the treatment of etanercept at 6 month. Continuation rate was statistically high in MTX cotherapy (93.3%) as compared with etanercept monotherapy (73.5%), and tended to be higher than non-MTX cotherapy (85.1%). Logistic regression analysis identified that MTX cotherapy at entry and moderate disease activity at entry are independent variables toward remission induction at 6 month. Accordingly, DAS28-ESR at 6 month was significantly low in MTX cotherapy as compared with etanercept monotherapy or non-MTX cotherapy. To a lesser extent, DAS28-ESR of non-MTX cotherapy at 6 month was lower than etanercept monotherapy.
Introduction
Randomized controlled trials of the anti-tumor necrosis factor  (anti-TNF ) therapies including etanercept in rheumatoid arthritis (RA) have shown etanercept to be superior to placebo and to methotrexate (MTX) monotherapy in patients with active RA (1, 2) .
The trial of Etanercept and Methotrexate with Radiografic Patient Outcomes (TEMPO) study compared etanercept with MTX, starting each as new monotherapy or both as combination therapy, and found the combination to be superior to either drug alone (3) .
However, the majority of patients in clinical practice who will receive etanercept will already received nonbiologic disease modifying antirheumatic drugs (DMARDs) including MTX yet have ongoing disease activity. In addition, the dosage as well as kinds of nonbiologic DMARDs on the "real-world" of RA in Japan are different from the western countries, thus, an evidence of "real-world" effectiveness of etanercept should be established in Japanese patients.
In this study, we have investigated whether baseline variables at treatment initiation are associated with clinical response to the treatment of etanercept, and shown that MTX cothrepay as well as the moderate disease activity are predictive for remission induction at 6 month. with non-MTX nonbiologic DMARDs (non-MTX cotherapy) at initiation and prednisolone at initiation. Prednisolone ＞5 mg/day at intiation was also examined for logistic regression analysis. P value less than 0.05 is considered to be significant. The reasons for discontinuation, judged by each physician, are the followings: In etanercept monotherapy group, one patient discontinued by lack of efficacy, skin eruption, angina pectoris or perforation of sigmoid colon. Six patients discontinued by respiratory tract infection. One patient complicated with 2 adverse events at the discontinuation. In non-MTX cotherapy group, one patient discontinued by lack of efficacy, itching of skin, compression fracture of the spine or sepsis. Three patients discontinued from respiratory tract infection. In MTX cotherapy group, one patient discontinued by elevation of liver enzymes or respiratory tract infection. Two patients discontinued by skin eruption. Table 2 shows the data of logistic regression analysis. As shown in Table 2A , MTX cotherapy and moderate disease activity at baseline were independent predictors toward remission induction at 6 month. The similar results were obtained if the dosage of prednisolone at initiation was limited as ＞5 mg/day (Table 2B ). Other variables of gender, non-MTX cotherapy, prednisolone at initiation did not reach to statistical significance. Accordingly, baseline variables among MTX cotherapy, non-MTX cotherapy and etanercept monotherapy were similar except for the slight difference of age at initiation (Table 3) 
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Baseline variables of 141 patients with RA treated with etanercept for 6 month and drug survival at 6 month
MTX cotherapy and moderate disease activity at initiation are independent predictors for DAS28-ESR remission at 6 months
Discussion
The results of this study support the benefit of the combined TEMPO study has identified lower disease activity at initiation is more likely to reach remission. Accordingly, moderate disease activity at entry is predictive toward remission induction as compared with the patients of high disease activity. Similar results are also obtained in Japanese RA patients treated with infliximab (8), suggesting that this demography may be common indicators for good therapeutic response of DMARDs in patients with RA.
There are limitations to comparing treatment outcomes based on observational data, since the decision to treat patients is not random, but is highly dependent on a number of factors, such as disease severity, patient choice and compliance, and comorbidities.
Similary, the decision to stop therapy because of inefficacy or adverse events in this "real-world" study was at the direction of the rheumatologist and was not subject to strict protocol. However, we still found a significant difference between the combined 
